267 related articles for article (PubMed ID: 32675150)
1. Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?
Kyriacou A; Melson E; Chen W; Kempegowda P
Clin Med (Lond); 2020 Jul; 20(4):417-423. PubMed ID: 32675150
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus.
Liao D; Liu C; Chen S; Liu F; Li W; Shangguan D; Shi Y
Int Immunopharmacol; 2023 Sep; 122():110414. PubMed ID: 37390646
[TBL] [Abstract][Full Text] [Related]
3. A case of pembrolizumab-induced fulminant Type 1 diabetes mellitus in breast cancer.
Tang Y; Zhao Z; Wang X; Zuo W; Zhang B; Yuan T; Fu Y
Immunotherapy; 2021 Apr; 13(6):483-489. PubMed ID: 33626915
[TBL] [Abstract][Full Text] [Related]
4. Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: A case report and review of 8 cases.
Ishiguro A; Ogata D; Ohashi K; Hiki K; Yamakawa K; Jinnai S; Tsutsui K; Takahashi A; Namikawa K; Yamazaki N
Medicine (Baltimore); 2022 Sep; 101(35):e30398. PubMed ID: 36107581
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus.
Hilder R; Tsai K; Quandt Z; Isaacs D; Drakaki A; Xing Y; In GK; Angell TE; Lechner MG
Front Endocrinol (Lausanne); 2023; 14():1242830. PubMed ID: 38027216
[TBL] [Abstract][Full Text] [Related]
6. Immune-Checkpoint Inhibitors-Induced Type 1 Diabetes Mellitus: From Its Molecular Mechanisms to Clinical Practice.
Cho YK; Jung CH
Diabetes Metab J; 2023 Nov; 47(6):757-766. PubMed ID: 37482654
[TBL] [Abstract][Full Text] [Related]
7. Predictors of the Onset of Type 1 Diabetes Obtained from Real-World Data Analysis in Cancer Patients Treated with Immune Checkpoint Inhibitors.
Takada S; Hirokazu H; Yamagishi K; Hideki S; Masayuki E
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1697-1699. PubMed ID: 32592366
[TBL] [Abstract][Full Text] [Related]
8. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes.
Chen X; Affinati AH; Lee Y; Turcu AF; Henry NL; Schiopu E; Qin A; Othus M; Clauw D; Ramnath N; Zhao L
Diabetes Care; 2022 May; 45(5):1170-1176. PubMed ID: 35238899
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitor-induced diabetes mellitus with pembrolizumab.
Zand Irani A; Almuwais A; Gibbons H
BMJ Case Rep; 2022 Jan; 15(1):. PubMed ID: 35039353
[TBL] [Abstract][Full Text] [Related]
11. Two cases with fulminant type 1 diabetes that developed long after cessation of immune checkpoint inhibitor treatment.
Hatayama S; Kodama S; Kawana Y; Otake S; Sato D; Horiuchi T; Takahashi K; Kaneko K; Imai J; Katagiri H
J Diabetes Investig; 2022 Aug; 13(8):1458-1460. PubMed ID: 35396830
[TBL] [Abstract][Full Text] [Related]
12. Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis.
Zhang AL; Wang F; Chang LS; McDonnell ME; Min L
Front Endocrinol (Lausanne); 2021; 12():620522. PubMed ID: 33927691
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes.
Kotwal A; Haddox C; Block M; Kudva YC
BMJ Open Diabetes Res Care; 2019; 7(1):e000591. PubMed ID: 30899528
[TBL] [Abstract][Full Text] [Related]
14. Characterization of immune checkpoint inhibitor-associated fulminant type 1 diabetes associated with autoantibody status and ethnic origin.
Qiu J; Luo S; Yin W; Guo K; Xiang Y; Li X; Liu Z; Zhou Z
Front Immunol; 2022; 13():968798. PubMed ID: 36451831
[TBL] [Abstract][Full Text] [Related]
15. Approach to the Patient With Immune Checkpoint Inhibitor-Associated Endocrine Dysfunction.
Wright JJ; Johnson DB
J Clin Endocrinol Metab; 2023 May; 108(6):1514-1525. PubMed ID: 36481794
[TBL] [Abstract][Full Text] [Related]
16. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
[TBL] [Abstract][Full Text] [Related]
17. Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.
Zezza M; Kosinski C; Mekoguem C; Marino L; Chtioui H; Pitteloud N; Lamine F
BMC Endocr Disord; 2019 Dec; 19(1):144. PubMed ID: 31870373
[TBL] [Abstract][Full Text] [Related]
18. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
Grimmelmann I; Momma M; Zimmer L; Hassel JC; Heinzerling L; Pföhler C; Loquai C; Ruini C; Utikal J; Thoms KM; Kähler KC; Eigentler T; Herbst RA; Meier F; Debus D; Berking C; Kochanek C; Ugurel S; Gutzmer R;
Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
[TBL] [Abstract][Full Text] [Related]
19. Clinical and HLA genotype analysis of immune checkpoint inhibitor-associated diabetes mellitus: a single-center case series from China.
Liu YC; Liu H; Zhao SL; Chen K; Jin P
Front Immunol; 2023; 14():1164120. PubMed ID: 37359544
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]